Trials	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
GENEVA, 2010 46-48	Low	Low	High: Personel administering treatments were not masked. Participants were masked to dose of implant, but not to treatment (steroid implant versus no implant).	Low	High: Macular thickness was described as a secondary outcome in the trial registry for one trial only, but the 6-month reported results used the pooled data from both trials to analyze this outcome at 6 months	Low	Unclear
ROVO, 2013 ⁴⁹	Low	Low	Unclear	Unclear	Low	Low	Unclear
SCORE, 2009 50-66	Low	Low	High: physicians and patients masked to dose but not triamcinolone versus observation	Low	 High: In the observation arm, 17% of participants had missing data compared with the 6.8% observed risk for the primary outcome. Reasons for missing data were not reported. 	Low	Unclear

Appendix 5 Risk of bias of individual studies

Trials	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
CRUISE,	Low	Unclear	Low	Low	Unclear	Low	Unclear
2010 67-69 ROCC,							
2010 ⁷⁰ COPERNICUS,	Unclear	Low	Low	Low	Unclear	Low	Unclear
	Low	Unclear	Low	Low	Unclear	Low	Low
2012 71-72							
GALILEO ,	Unclear	Unclear	Low	Low	Unclear	Low	Unclear
2013 73-74 EPSTEIN,		-	_	_	-	-	-
2012 75-77	Unclear	Low	Low	Low	Low	Low	Low
Wroblewski,	Low	Low	Low	Low	Unclear	Low	Unclear
2009 23, 78-83			Uch. Decence WT				
	Low	Low	High: Because IVT might cause floaters, we				
Ramezani, 2014 ⁸⁴			did not consider this	Low	Low	Low	Unclear
			study as a double-blind				
			one.				
COMRADE-C, 2016 ⁸⁵	Low	Low	Low	Low	Unclear	Low	Unclear